Get started
Elevation Oncology, Inc.Elevation Oncology, Inc.Elevation Oncology, Inc.

Elevation Oncology, Inc.

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

ELEV chart


Full chart

ELEV upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪33.90 M‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−0.8074 USD
Net income (FY)
‪−45.70 M‬ USD
Revenue (FY)
0.00 USD
Shares float
‪52.02 M‬
Beta (1Y)
4.05

Employees


Employees (FY)
29
Change (1Y)
−4 −12.12%
Revenue / Employee (1Y)
0.00 USD
Net income / Employee (1Y)
‪−1.58 M‬ USD

About Elevation Oncology, Inc.


Sector
Health Technology
Industry
Biotechnology
CEO
Joseph J. Ferra
Website
elevationoncology.com
Headquarters
Boston
Founded
2019
FIGI
BBG00W7CX151
Elevation Oncology, Inc. is a precision oncology company, which engages in the development of targeted therapeutics for the treatment of cancer in genomically-defined patient populations. The firm’s program is focused on patients with advanced solid tumors harboring an NRG1 fusion. The company was founded by Shawn M. Leland in 2019 and is headquartered in Boston, MA.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

ELEV news



Ideas



See all ideas 

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Sparks


Curated watchlists where ELEV is featured.

See all sparks 

Frequently Asked Questions


The current price of ELEV is 0.5639 USD — it has decreased by −1.67% in the past 24 hours. Watch Elevation Oncology, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Elevation Oncology, Inc. stocks are traded under the ticker ELEV.
ELEV stock has fallen by −13.25% compared to the previous week, the month change is a −7.59% fall, over the last year Elevation Oncology, Inc. has showed a 19.98% increase.
We've gathered analysts' opinions on Elevation Oncology, Inc. future price: according to them, ELEV price has a max estimate of 10.00 USD and a min estimate of 5.00 USD. Watch ELEV chart and read a more detailed Elevation Oncology, Inc. stock forecast: see what analysts think of Elevation Oncology, Inc. and suggest that you do with its stocks.
ELEV reached its all-time high on Jul 12, 2021 with the price of 16.2200 USD, and its all-time low was 0.3630 USD and was reached on Nov 13, 2023. View more price dynamics on ELEV chart.
See other stocks reaching their highest and lowest prices.
ELEV stock is 8.09% volatile and has beta coefficient of 4.05. Track Elevation Oncology, Inc. stock price on the chart and check out the list of the most volatile stocks — is Elevation Oncology, Inc. there?
Today Elevation Oncology, Inc. has the market capitalization of ‪33.90 M‬, it has decreased by −14.38% over the last week.
Yes, you can track Elevation Oncology, Inc. financials in yearly and quarterly reports right on TradingView.
Elevation Oncology, Inc. is going to release the next earnings report on Mar 5, 2025. Keep track of upcoming events with our Earnings Calendar.
ELEV earnings for the last quarter are −0.22 USD per share, whereas the estimation was −0.19 USD resulting in a −15.79% surprise. The estimated earnings for the next quarter are −0.23 USD per share. See more details about Elevation Oncology, Inc. earnings.
Elevation Oncology, Inc. revenue for the last quarter amounts to 0.00 USD, matching the estimated figure, and no changes in revenue are expected for the next quarter.
ELEV net income for the last quarter is ‪−12.88 M‬ USD, while the quarter before that showed ‪−10.46 M‬ USD of net income which accounts for −23.13% change. Track more Elevation Oncology, Inc. financial stats to get the full picture.
No, ELEV doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 25, 2024, the company has 29.00 employees. See our rating of the largest employees — is Elevation Oncology, Inc. on this list?
Like other stocks, ELEV shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Elevation Oncology, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Elevation Oncology, Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Elevation Oncology, Inc. stock shows the strong sell signal. See more of Elevation Oncology, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.